Everyday cognitive failure in patients suffering from neurosarcoidosis

Mareye Voortman; Jolanda De Vries; Celine M. R. Hendriks; Marjon D. P. Elfferich; Petal A. H. M. Wijnen; Marjolein Drent

doi:10.36141/svdld.v36i1.7412

Everyday cognitive failure in patients suffering from neurosarcoidosis

Mareye Voortman^*, Jolanda De Vries, Celine M. R. Hendriks, Marjon D. P. Elfferich, Petal A. H. M. Wijnen, Marjolein Drent

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Web of Science)

Abstract

Background: Cognitive failure is associated with memory and concentration problems. Previously, a prevalence of one third was found in a general sarcoidosis population. The aim of this study was to assess if neurosarcoidosis patients are at higher risk for developing everyday cognitive failure using the Cognitive Failure Questionnaire (CFQ) and to determine what factors were associated with cognitive failure. Methods: A cross-sectional web-based survey was conducted from April to May 2017 in a national sample of neurosarcoidosis patients. The survey asked about complaints and included 3 questionnaires (Fatigue Assessment Scale [FAS], Small Fiber Neuropathy Screening List [SFNSL] and CFQ. Data were compared to a general sarcoidosis population. Results: Of the 152 patients who completed the survey, 131 had neurosarcoidosis. The mean CFQ score was significantly higher in the neurosarcoidosis (45.6 +/- 20.7) compared to the general sarcoidosis population (36.2 +/- 15.9; p<0.0001). High CFQ scores (>= 43) were found in 55.7% and 33.9%, respectively (p

Original language	English
Pages (from-to)	2-10
Number of pages	9
Journal	Sarcoidosis Vasculitis and Diffuse Lung Diseases
Volume	36
Issue number	1
DOIs	https://doi.org/10.36141/svdld.v36i1.7412
Publication status	Published - 2019

Keywords

neurosarcoidosis
cognitive failure
small fiber neuropathy (SFN)
fatigue
sarcoidosis
SMALL-FIBER NEUROPATHY
SARCOIDOSIS
FATIGUE
PREVALENCE
QUALITY
SLEEP

Access to Document

10.36141/svdld.v36i1.7412

http://mattioli1885journals.com/index.php/sarcoidosis/article/view/7412

Cite this

@article{c8d2ccc0a03146b9ba2dcdaf147733fe,

title = "Everyday cognitive failure in patients suffering from neurosarcoidosis",

abstract = "Background: Cognitive failure is associated with memory and concentration problems. Previously, a prevalence of one third was found in a general sarcoidosis population. The aim of this study was to assess if neurosarcoidosis patients are at higher risk for developing everyday cognitive failure using the Cognitive Failure Questionnaire (CFQ) and to determine what factors were associated with cognitive failure. Methods: A cross-sectional web-based survey was conducted from April to May 2017 in a national sample of neurosarcoidosis patients. The survey asked about complaints and included 3 questionnaires (Fatigue Assessment Scale [FAS], Small Fiber Neuropathy Screening List [SFNSL] and CFQ. Data were compared to a general sarcoidosis population. Results: Of the 152 patients who completed the survey, 131 had neurosarcoidosis. The mean CFQ score was significantly higher in the neurosarcoidosis (45.6 +/- 20.7) compared to the general sarcoidosis population (36.2 +/- 15.9; p<0.0001). High CFQ scores (>= 43) were found in 55.7% and 33.9%, respectively (p",

keywords = "neurosarcoidosis, cognitive failure, small fiber neuropathy (SFN), fatigue, sarcoidosis, SMALL-FIBER NEUROPATHY, SARCOIDOSIS, FATIGUE, PREVALENCE, QUALITY, SLEEP",

author = "Mareye Voortman and {De Vries}, Jolanda and Hendriks, {Celine M. R.} and Elfferich, {Marjon D. P.} and Wijnen, {Petal A. H. M.} and Marjolein Drent",

note = "Funding Information: This study was supported by a research grant from the ild care foundation: www.ildcare.nl. M.V. is supported by a research grant from the Netherlands Organization for Health Research and Development, ZonMw (project number 842002005). The study sponsors had no involvement in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} Mattioli 1885.",

year = "2019",

doi = "10.36141/svdld.v36i1.7412",

language = "English",

volume = "36",

pages = "2--10",

journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",

issn = "1124-0490",

publisher = "Mattioli 1885 S.p.A.",

number = "1",

}

TY - JOUR

T1 - Everyday cognitive failure in patients suffering from neurosarcoidosis

AU - Voortman, Mareye

AU - De Vries, Jolanda

AU - Hendriks, Celine M. R.

AU - Elfferich, Marjon D. P.

AU - Wijnen, Petal A. H. M.

AU - Drent, Marjolein

N1 - Funding Information: This study was supported by a research grant from the ild care foundation: www.ildcare.nl. M.V. is supported by a research grant from the Netherlands Organization for Health Research and Development, ZonMw (project number 842002005). The study sponsors had no involvement in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication. Publisher Copyright: © Mattioli 1885.

PY - 2019

Y1 - 2019

N2 - Background: Cognitive failure is associated with memory and concentration problems. Previously, a prevalence of one third was found in a general sarcoidosis population. The aim of this study was to assess if neurosarcoidosis patients are at higher risk for developing everyday cognitive failure using the Cognitive Failure Questionnaire (CFQ) and to determine what factors were associated with cognitive failure. Methods: A cross-sectional web-based survey was conducted from April to May 2017 in a national sample of neurosarcoidosis patients. The survey asked about complaints and included 3 questionnaires (Fatigue Assessment Scale [FAS], Small Fiber Neuropathy Screening List [SFNSL] and CFQ. Data were compared to a general sarcoidosis population. Results: Of the 152 patients who completed the survey, 131 had neurosarcoidosis. The mean CFQ score was significantly higher in the neurosarcoidosis (45.6 +/- 20.7) compared to the general sarcoidosis population (36.2 +/- 15.9; p<0.0001). High CFQ scores (>= 43) were found in 55.7% and 33.9%, respectively (p

AB - Background: Cognitive failure is associated with memory and concentration problems. Previously, a prevalence of one third was found in a general sarcoidosis population. The aim of this study was to assess if neurosarcoidosis patients are at higher risk for developing everyday cognitive failure using the Cognitive Failure Questionnaire (CFQ) and to determine what factors were associated with cognitive failure. Methods: A cross-sectional web-based survey was conducted from April to May 2017 in a national sample of neurosarcoidosis patients. The survey asked about complaints and included 3 questionnaires (Fatigue Assessment Scale [FAS], Small Fiber Neuropathy Screening List [SFNSL] and CFQ. Data were compared to a general sarcoidosis population. Results: Of the 152 patients who completed the survey, 131 had neurosarcoidosis. The mean CFQ score was significantly higher in the neurosarcoidosis (45.6 +/- 20.7) compared to the general sarcoidosis population (36.2 +/- 15.9; p<0.0001). High CFQ scores (>= 43) were found in 55.7% and 33.9%, respectively (p

KW - neurosarcoidosis

KW - cognitive failure

KW - small fiber neuropathy (SFN)

KW - fatigue

KW - sarcoidosis

KW - SMALL-FIBER NEUROPATHY

KW - SARCOIDOSIS

KW - FATIGUE

KW - PREVALENCE

KW - QUALITY

KW - SLEEP

U2 - 10.36141/svdld.v36i1.7412

DO - 10.36141/svdld.v36i1.7412

M3 - Article

C2 - 32476930

SN - 1124-0490

VL - 36

SP - 2

EP - 10

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

IS - 1

ER -